role of adaptive vs. innate immune activation in non-aids morbidity
DESCRIPTION
Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity. Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division. A shift in focus…. T cell activation as a target for interventions in the pre-ART era - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/1.jpg)
Role of Adaptive vs. Innate Immune Activation innon-AIDS Morbidity
Peter W. Hunt, MDAssociate Professor of Medicine
UCSF HIV/AIDS Division
![Page 2: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/2.jpg)
A shift in focus…
• T cell activation as a target for interventions in the pre-ART era
• Monocyte activation and inflammation a target during treated HIV disease
• Why this shift is occurring– Important caveats
• Implications for future clinical trials
![Page 3: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/3.jpg)
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency
MS Gottlieb, R Schroff, HM Schanker, JD Weisman, PT Fan, RA Wolf, and A Saxon
Dec 10, 1981
T10=CD38
Leu3=CD4
![Page 4: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/4.jpg)
CD8+ T cell activation predicts survival better than VL
in patients with AIDS (CD4<200)
Janice Giorgi
Giorgi, JID, 1999 (see also: Giorgi, JAIDS, 2002)
Survival
P=0.02
Survival
P=0.001
![Page 5: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/5.jpg)
T Cell Activation Declines with ART
Hunt et al, JID, 2003; PLoS One, 2011
![Page 6: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/6.jpg)
But Remains Abnormally High During ART-mediated Viral Suppresion
Hunt et al, JID, 2003; PLoS One, 2011
![Page 7: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/7.jpg)
Is T cell activation a cause of disease in treated HIV infection or
simply a marker for some other process?
Important for identifying targets for novel interventions
![Page 8: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/8.jpg)
Low CD4 Count during ART Predicts non-AIDS Death
Young et al for COHERE cohort, PLoS Med, 2012 (see also Baker, AIDS, 2008)
![Page 9: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/9.jpg)
IL-2 Increases CD4 Counts in Treated Patients
Abrams et al, NEJM, 2009
IL-2 also decreases HLA-DR and CD38 expression(Kovacs, NEJM, 1995)
![Page 10: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/10.jpg)
However, IL-2 Had No Effect on AIDS/Death
Abrams et al, NEJM, 2009
P=0.47
P=0.55
CD4 count (and CD38 / DR expression) is not 100% specific for the pathophysiologic pathway mediating disease.
![Page 11: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/11.jpg)
Why didn’t IL-2 work?
• May have expanded the wrong type of CD4+ T cells (regulatory cells).– Impaired functional immune responses?
• Could CD4+ T cell count just be a marker for some other immunologic process?
![Page 12: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/12.jpg)
What Specific Immunologic Pathways are Driving Disease during ART?
Non-AIDSMorbidity /Mortality
Innate Immune Activation(MØ/DC)
CD4Lymphopenia
Inflammation
T and B CellActivation/
Dysfunction
?
?
?
Coagulation ?
![Page 13: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/13.jpg)
What Specific Immunologic Pathways are Driving Disease during ART?
Non-AIDSMorbidity /Mortality
Innate Immune Activation(MØ/DC)
CD4Lymphopenia
Inflammation
T and B CellActivation/
Dysfunction
?
?
?
Coagulation ?
X
![Page 14: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/14.jpg)
Hunt et al, JID, 2003 (see also Goicoechea, JID, 2006; Gandhi, JAIDS, 2006)
High T Cell Activation Associated with Blunted CD4 Recovery during ART
![Page 15: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/15.jpg)
Lederman et al., JID, 2011
Inflammation and Innate Immune Activation are Increased in Patients with
Poor CD4+ T cell Recovery on ARTIL-6 sCD14
CD4<350 CD4>500 HIV- CD4<350 CD4>500 HIV-
![Page 16: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/16.jpg)
How do we get a better sense of the specific immunlogic
pathways driving disease?
![Page 17: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/17.jpg)
Eden et al., JID , 2007 (see also: Burdo, AIDS, 2013; Lyons, JAIDS, 2011; Letendre, CROI 2012, Abstract #82)
Abnormal CSF Neopterin Levels Persist Despite 4 Years of VL Suppression
60% Abnormal
![Page 18: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/18.jpg)
Sinclair, JAIDS, 2008
CD8+ T Cell Activation is Not Persistently Elevated in CSF During Suppressive ART
T cell activation in the CNS is unlikely to explain persistent neurocognitive dysfunction in ART-suppressed individuals
![Page 19: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/19.jpg)
Baker, CROI 2013, Abstract #66LB
Monocyte Activation Predicts Coronary Artery Calcium Progression: SUN Study
T cell Activation
Not Predictive
![Page 20: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/20.jpg)
Do these markers predict clinical events?
![Page 21: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/21.jpg)
SMART: Inflammatory Markers Strongly Associated with Mortality and CVD Events
BiomarkerAll-Cause Mortality
(N=85)Fatal or Non-fatal CVD
(N=136)
OR P-value OR P-value
hs-CRP 3.1 0.02 1.6 0.20
IL-6 12.4 <0.0001 2.8 0.003
Amyloid A 3.1 0.05 1.6 0.12
Amyloid P 1.1 0.78 2.8 0.002
D-dimer 41.2 <0.0001 2.0 0.06
F1.2 1.3 0.64 0.8 0.56
Kuller L et al. PLoS Med, 2008; Duprez, Atherosclerosis, 2009Even after adjusting for CD4 count!
![Page 22: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/22.jpg)
Hunt, CROI 2012, Abstr #278 (see also : Tenorio, CROI 2013, Abstr# 790)
Innate Immune Activation Predicts Mortality More Strongly than T Cell Activation: SOCA
Gut Epithelial Barrier Dysfunction
Inflammation / Coagulation
Matched for age, gender, duration VL suppression, CMV retinitis, nadir CD4
IDO-1 Induction
Monocyte Activation
![Page 23: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/23.jpg)
Hunt, CROI 2012, Abstr #278 (see also : Tenorio, CROI 2013, Abstr# 790)
Innate Markers Predict Mortality Independent of Nadir AND Current CD4 count
Gut Epithelial Barrier Dysfunction
Inflammation / Coagulation
Also adjusted
for currentCD4
count
IDO-1 Induction
Monocyte Activation
Current CD4 count no longer predictive of mortality after
adjusting for innate markers
![Page 24: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/24.jpg)
Why does T cell “senescence” not predict mortality in HIV
infection?
![Page 25: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/25.jpg)
Antigen
CD57+,↓Telomere
Length
A: Normal CD8+ T Cell Proliferation & Maturation
Central Memory Transitional TEMRAEffector Memory
CD28- Memory CD8+ CellsCD28+CD27+CCR7+RA- CD27+CCR7-RA- CD27-CCR7-RA- CD27-CCR7-RA+
CD57-,↑Telomere
Length
Antigen
Inflammatory Cytokines
B: Maturational/Proliferative Defect in HIV
IDO-1,PD-1+ Monocytes
Central Memory Transitional TEMRAEffector Memory
CD28- Memory CD8+ CellsCD28+CD27+CCR7+RA- CD27+CCR7-RA- CD27-CCR7-RA- CD27-CCR7-RA+
Lee, CROI 2013, #294
![Page 26: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/26.jpg)
Antigen
CD57+,↓Telomere
Length
A: Normal CD8+ T Cell Proliferation & Maturation
Central Memory Transitional TEMRAEffector Memory
CD28- Memory CD8+ CellsCD28+CD27+CCR7+RA- CD27+CCR7-RA- CD27-CCR7-RA- CD27-CCR7-RA+
CD57-,↑Telomere
Length
Antigen
Inflammatory Cytokines
B: Maturational/Proliferative Defect in HIV
IDO-1,PD-1+ Monocytes
Central Memory Transitional TEMRAEffector Memory
CD28- Memory CD8+ CellsCD28+CD27+CCR7+RA- CD27+CCR7-RA- CD27-CCR7-RA- CD27-CCR7-RA+
Lee, CROI 2013, #294
![Page 27: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/27.jpg)
HIV Disease Drives Expansion of CD28- CD8+ T Cells . . .
All CMV+ Lee, CROI 2013, #309
P=0.0002P=0.10
![Page 28: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/28.jpg)
But CD57 is inappropriately low onCD28- CD8+ T Cells in HIV infection
All CMV+ Lee, CROI 2013, #309
P<0.0001P=0.0003
![Page 29: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/29.jpg)
Low (Not High) CD57 on CD28- CD8+ T Cells Predicts Mortality in Treated HIV
*Subjects matched on age, gender, duration of viral suppression, presence of CMV retinitis, and nadir CD4+ cell count Lee, CROI 2013, #309
![Page 30: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/30.jpg)
Higher Monocyte Activation Associated with the Low CD57 CD8+ T cell Defect
Lee, CROI 2013, #309
Monocyte activation may cause T cell proliferative defects in HIV by:
• PD1-driven IL-10 release (Said, Nat Med, 2010)
• IDO-1 induction (Boasso, Blood, 2007)
![Page 31: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/31.jpg)
What Specific Immunologic Pathways are Driving Disease during ART?
Non-AIDSMorbidity /Mortality
Innate Immune Activation(MØ/DC)
CD4Lymphopenia
Inflammation
T and B CellActivation/
Dysfunction
?
?
Coagulation
![Page 32: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/32.jpg)
Caveats…
![Page 33: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/33.jpg)
T / B Cell Activation Predicts NHL (MACS)
Breen, Cancer Epi Bio, 2011
Adjusted for age, duration HIV infection, and CD4 count
![Page 34: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/34.jpg)
T Cell Activation may be an important contributor to HIV reservoir size…
Hatano, JID, 2013
![Page 35: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/35.jpg)
Implications for Clinical Trials
![Page 36: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/36.jpg)
CD8 Activation is a Reproducible and Responsive Marker
Hunt, Blood, 2013
Placebo Arm
Std Devof ∆ Wk 0-24:
0.13 log10%
~35% relative
change
![Page 37: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/37.jpg)
Lots of Within-subject Variability in IL-6
Std Devof ∆ Wk 0-24:
0.38 log10pg/ml
~2.4-fold relative change
Hunt, Blood, 2013
![Page 38: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/38.jpg)
sCD14 is much better, comparable variability to T cell activation
Std Devof ∆ Wk 0-24:
0.11 log10ug/ml
~29%relative change
Hunt, Blood, 2013
![Page 39: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/39.jpg)
• Several immunologic defects predict disease in treated HIV infection:– Innate immune activation and inflammation– CD4 lymphopenia– T cell / B bell activation and dysfunction
• Innate immune activation and inflammation independently predict disease, less consistent for other markers.
• Interventions designed to decrease activation of myeloid lineage cells may hold promise.– Statins, ASA?– Microbial Translocation interventions– Treating co-infections?
Summary
![Page 40: Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity](https://reader036.vdocument.in/reader036/viewer/2022062323/56816616550346895dd96340/html5/thumbnails/40.jpg)
AcknowledgementsNIAIDJason BrenchleyDanny DouekIrini Sereti
Core Immunology Lab/DEMElizabeth SinclairLorrie EplingMike McCune
SOCACurtis MeinertMark Van Natta
ACTGHeather Ribaudo
SCOPE/OPTIONS/UCSFSulggi LeeSteve DeeksJeff Martin Hiroyu HatanoVivek JainRebecca HohRick Hecht
CWRUWei JiangMichael LedermanNick FunderburgBrian Claggett
U MinnesotaJason Baker
R56AI100765, 1R21AI087035, 1R21AI07877, DDCF CSDA